The U.S. Food and Drug Administration (FDA) has announced a funding opportunity aimed at supporting clinical trials for orphan products that address unmet needs in rare diseases. This initiative seeks to enhance the approval of treatments for over 7,000 rare diseases affecting approximately 30 million Americans, encouraging innovative trial designs and collaboration among stakeholders such as industry, academia, and patient organizations. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and various government entities, with funding available up to $650,000 annually for a maximum of four years. Interested parties should submit their applications by September 22, 2024, and can contact Shashi Malhotra at shashi.malhotra@fda.hhs.gov for further information.